Silvia A. Trinidad
International Dermatology Research, Inc.
8370 West Flagler, St. Suite 200
Miami, FL 33144
Currently Enrolling Trials
International Dermatology Research (IDR) is a privately owned research company and private practice specializing in dermatology. Established in 1993, it has successfully completed more than 600 clinical trials. Our staff is composed of two dermatologists, one nurse practitioner, two medical assistants, one aesthetician, two receptionists, one supervisor, three research coordinators, one general administrator/research director and three clinical research monitors.
IDR also counts with 10 sites in Latin America, located in the following countries: Honduras (three sites), El Salvador (two sites), Panama (two sites) Dominican Republic (four sites) and Guatemala (one site). Most of our sites have more than 20 years of experience conducting clinical trials. All research staff is trained on GCP and ICH guidelines.
Our centers conduct phase II to IV studies, mainly in regular dermatology, but also in cosmetics and dermatology-related devices. In addition, three of our Latin American sites have the ability to conduct women's health studies. Among our clients are most major pharma as well as generics companies, and we can proudly state that several generic and brand-name medications have been FDA-approved based solely on the data provided by our centers. Furthermore, one of our sites in Honduras and one in the Dominican Republic have the capability to conduct phase I trials with vast experience in pediatrics PKs.
Our research experience is comprised of the following therapeutic areas:
- Actinic Keratosis
- Atopic Dermatitis(Adults and Pediatrics)
- Diaper Dermatitis
- Genital Warts
- Hand Dermatitis
- Hypertrophic scars
- Hidradenitis Suppurativa
- Ichthyosis Vulgaris
- Impetigo (over 4,500 cases conducted)
- Lamellar Ichthyosis
- Lice Infestation
- Patch Testing
- Palmoplantar Keratosis
- Polymorphic Light Eruption
- Psoriasis(Adults and Pediatrics)
- Seborrheic Dermatitis
- Secondary Skin Infection
- Solar Lentigines
- Tinea Capitis
- Tinea Corporis
- Tinea Cruris
- Tinea Pedis
- Tinea Versicolor
- Transdermal Devices
- Urinary Tract Infection
- Vulvo Vaginal Candidiasis
- Vulvo Vaginal Atrophy
Our headquarters is located on one of Miami's main arteries, close to expressways and 10 minutes away from Miami International Airport and major hotel chains, such as Marriott, Hilton, Intercontinental, etc.
The office features 5,500 square feet of space with 3,000 square feet dedicated to clinical research, 1,000 to regular dermatology practice and 1,500 to archiving. In addition, we have a CLIA-certified laboratory, set with -20º C and -70º C freezers for PK studies. Additionally, there are two fully customized monitoring areas with phones, internet connection, sound-proofed walls, refrigerator, coffee machine, copy/fax machine as well as an ample conference room equipped with TV.
Eduardo Weiss, MD
Graduate Doctor of Medicine, Central University of Venezuela
Dermatology Residency, Jackson Memorial Hospital
Wound Healing Fellowship, University of Miami
David Rodriguez MD
Dermatology Residency, University of Illinois
Medical School University of Illinois Chicago
Fellowship, Jackson Memorial Hospital
Silvia A. Trinidad
40 years of experience in supervising clinical research and managing studies in the U.S. and Latin America
Ariel F. Sotolongo, ARNP – Foreign MD
Efren Mendez, --Foreign MD
Clinical Trial Manager
Odett Reina Suarez, Coordinator
Mabel Canizares, Pharmacy Tech
Delvis Jimenez, Foreign MD
Clinical Research Coordinator
The patients population at our Miami headquarters office consists of White, Hispanic and African American patients and covers pediatrics to geriatrics. Patients in our database come mainly from Dade and Broward counties.
Since we specialize mainly in dermatology, our staff has a vast experience in all dermatological- related conditions, giving us the ability to deliver very accurate data in a timely fashion. Furthermore, having 13 additional sites in Latin America allows us to facilitate fast enrollment with 95 percent compliance even in studies of rare conditions difficult to conduct in the U.S.
IDR has an impressive record of 10 FDA inspections in the past nine years without any findings or observations.